Conflicts of interest statement: There are no conflicts of interest. “
“Viral clearance of acute HBV infection depends on a rigorous CD4+ and CD8+ T-cell-mediated response directed against HBV-specific antigens that includes production of interferon (IFN)-γ [1], [2], [3] and [4]. In patients with chronic HBV infection, T-cell responses and IFN-γ production are both severely impaired, contributing to the persistence of their HBV infection [1], [3] and [4]. Currently available drugs are capable of controlling this website viremia but rarely eradicate the virus [5]. Therefore, to achieve a cure (defined as hepatitis B surface antigen [HBsAg] seroconversion),
new therapies targeting HBV replication and the immune system are needed [5]. GS-4774 (formerly GI-13020) is being developed to elicit an HBV-specific T-cell immune response in patients with chronic HBV infection. GS-4774 consists of heat-inactivated yeast cells that express well-conserved regions of HBV proteins, namely HBsAg, hepatitis B core antigen (HBcAg) and hepatitis B X protein (HBx) expressed as a single fusion protein. The recombinant heat-killed whole yeast platform has been previously shown to elicit a significant T-cell response upon subcutaneous administration [6]. Preclinical experiments
in mice showed that GS-4774 elicited T-cell responses specific to HBsAg, HBcAg, and HBx and stimulated HBV-specific CD8+ T-cells [7]. In cells from patients with chronic Oxymatrine HBV infection, GS-4774 induced IFN-γ-producing CD4+ and CD8+ T cells that, in some cases, showed marked levels of expression GSK2118436 in vivo of the Lamp-1/CD107a marker of cytotoxic function [8]. These experiments suggested that GS-4774 had potential to elicit an antiviral immune response. The present work was a first-time-in-human clinical trial of GS-4774 in healthy subjects. Healthy subjects aged ≥18 years were eligible. Subjects were recruited using
a database of healthy volunteers elicited using advertisements in the community. Before enrolment, subjects had to demonstrate negative immunoglobulin (Ig) E-mediated hypersensitivity to Saccharomyces cerevisiae. Detailed exclusion criteria are provided in Supplementary File 1. All patients were negative for HBV DNA and anti-HBc antibodies. Four subjects had low-level antibodies to HBsAg below the threshold for positivity. All subjects provided informed consent prior to screening. Local Ethics Review Committees approved the study, which was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. Single-site, randomized, open-label, dose-ascending, multi-arm study conducted in the USA between January and July 2013. Subjects were allocated to one of three dose groups (n = 20 per group) to receive 10, 40 or 80 yeast units (YU) (1 YU = 107 yeast cells) of study treatment.